{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:43:06Z","timestamp":1791405786756,"version":"4.3.3"},"reference-count":18,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate\u2010to\u2010severe atopic dermatitis. Herein we describe the time\u2010course of drug\u2010induced platelet reduction following abrocitinib administration, identify covariates affecting platelet counts, and determine the probability of patients experiencing thrombocytopaenia while receiving abrocitinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This analysis included data from two Phase 2 and three Phase 3 studies in psoriasis and atopic dermatitis patient populations administered abrocitinib 10\u2013400\u2009mg QD orally for up to 12\u2009weeks, with platelet counts determined up to week 16. A semi\u2010mechanistic model was developed to assess the impact of baseline platelet counts (170, 220 and 270\u2009\u00d7\u20091000\/\u03bcL), age and race on the platelet nadir and week 12 counts with once\u2010daily abrocitinib 200\u2009mg or 100\u2009mg.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Decreases in platelet counts were transient with the nadir occurring on average 24\u2009days (95% prediction interval, 23\u201324) after continuous administration of abrocitinib 200\u2009mg QD. Following administration of once\u2010daily abrocitinib 200\u2009mg, the probabilities of thrombocytopaenia (&lt;150\u2009\u00d7\u20091000\/\u03bcL) at the nadir were 8.6% and 95.5% for the typical patient with baseline platelet count of 270\u2009\u00d7\u20091000\/\u03bcL or 170\u2009\u00d7\u20091000\/\u03bcL, respectively. Adolescents had a lower probability of thrombocytopaenia compared with adults; platelet count distribution was similar in Asian and Western patients at the nadir and at week 12.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This analysis supports the safety of once\u2010daily abrocitinib 200\u2009mg and 100\u2009mg dosing regimens, with low probability of thrombocytopaenia during treatment, except for higher risk of low\u2010grade thrombocytopaenia that diminished after 4\u00a0weeks in patients with low baseline platelet counts.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15334","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T05:39:40Z","timestamp":1648445980000},"page":"3856-3871","source":"Crossref","is-referenced-by-count":13,"title":["Population pharmacokinetic\u2010pharmacodynamic modelling of platelet time\u2010courses following administration of abrocitinib"],"prefix":"10.1111","volume":"88","author":[{"given":"Jessica","family":"Wojciechowski","sequence":"first","affiliation":[{"name":"Pfizer Inc.  Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal K.","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxing","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Fostvedt","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Nicholas","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01598"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(20)30732\u20107"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16004"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/moh.0000000000000170"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12548"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010021\u201001104\u2010z"},{"key":"e_1_2_10_10_1","volume-title":"NONMEM User's Guides (1989\u20132009)","author":"Beal SL","year":"2009"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_2_10_13_1","unstructured":"R Core Team.R: A Language and Environment for Statistical Computing. Vienna Austria: R Foundation for Statistical Computing.https:\/\/www.R-project.org\/. Accessed July 22 2020."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.140"},{"key":"e_1_2_10_15_1","unstructured":"US Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE). Version 50 2017."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14752"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3770"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12419"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.043042"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15334","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15334","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:00:57Z","timestamp":1692680457000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/bcp.15334"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15334","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]}}}